Here, we reveal that therapy efficacy is greatly improved through previously unrecognized effects of VEGFR2 inhibition on tumor stroma in esophagogastric adenocarcinoma. The gene discussed is KDR; the disease is gastroesophageal junction adenocarcinoma.